Vistagen Therapeutics (VTGN) Operating Expenses (2011 - 2026)

Vistagen Therapeutics has disclosed Operating Expenses across 16 years of filings, most recently posting $14.8 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 7.63% year-over-year to $14.8 million; the TTM figure through Jun 2026 stood at $72.2 million (up 19.69% YoY), while the FY2026 annual figure was $73.4 million, up 30.0% from the prior year.
• Operating Expenses came in at $14.8 million for Q2 2026 at Vistagen Therapeutics, down from $17.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $20.3 million in Q3 2025 to a low of $7.1 million in Q3 2023.
• Average Operating Expenses over 5 years is $14.1 million, with a median of $14.7 million recorded in 2025.
• Year-over-year, Operating Expenses surged 151.19% in 2022 and plunged 64.27% in 2023.
• Over 5 years, Operating Expenses stood at $9.9 million in 2022, then dropped by 16.6% to $8.3 million in 2023, then jumped by 85.1% to $15.4 million in 2024, then increased by 29.28% to $19.8 million in 2025, then retreated by 25.32% to $14.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $14.8 million in Q2 2026, $17.2 million in Q1 2026, and $19.8 million in Q4 2025.